《绩後表现》中生制药(01177.HK)早段挫约4% 大摩指第三季经常性纯利略逊
中生制药(01177.HK)今早(27日)低开约2.7%报10.9元後,初段跌幅扩大,曾跌最多4.5%,低见10.7元,届今早约10时07分,报10.76元,跌幅约3.9%,成交2,231万股,涉近2.42亿元。
公司上日(26日)收市後公布首三季业绩,营业额193.21亿元人民币(下同),按年升22.8%。纯利22.56亿元,按年升2.5%;每股盈利17.92分。派季度息2港仙,上年同期派2港仙。
摩根士丹利发表研究报告,指中生制药第三季增长对办,销售按年升13%符该行预期,经常性纯利升17%则略逊预期,予「增持」评级,目标价12.5元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.